The Trump Administration is reportedly poised to issue an executive order that would affect the production of medicines, FDA-regulated emergency medical countermeasures, and active pharmaceutical ingredients. This is a terrible idea, especially during a pandemic…
Read MoreU.S. Senator Chuck Grassley (R-Iowa) is making a big push for new cosponsors of the Prescription Drug Pricing Reduction Act (PDPRA, a.k.a. the Grassley-Wyden Prescription Drug Bill), building off of President Trump’s mention of reducing prescription drug prices during his 2020 State of the Union address. Although Sen. Grassley has had trouble getting Republican Cosponsors in past, the State of the Union address has emboldened his staff to recirculate a recruitment letter, netting Sens. McSally (R-Arizona) and bringing the bill up to almost a dozen Republican cosponsors…
Read MoreThe Trump administration has been toying with the idea of implementing an international pricing index (IPI) model for Medicare Part B drugs and biologicals. The ostensible goal of the model would be to lower drug prices. This supposedly would be accomplished by pegging the price that the Medicare system pays for drugs to a level closer to the prices paid in a collection of other countries…
Read More
The Trump Administration has been toying with the idea of implementing an international pricing index (IPI) model for Medicare Part B drugs and biologicals. The ostensible goal of the model would be to lower drug prices. This supposedly would be accomplished by pegging the price that the Medicare system pays for drugs to a level closer to the prices paid in a collection of other countries…
Read MoreThe Trump Administration has been toying with the idea of implementing an international pricing index (IPI) model for Medicare Part B drugs and biologicals. The ostensible goal of the model would be to lower drug prices. This supposedly would be accomplished by pegging the price that the Medicare system pays for drugs to a level closer to the prices paid in a collection of other countries…
Read MoreOn January 16, after more than a year of negotiations with Canada and Mexico, the U.S. Senate passed the implementing bill for the U.S.-Mexico-Canada Agreement, which preserves and strengthens our economic ties with Mexico and Canada—our top two export markets—and guarantees that virtually all U.S. exports enter these markets tariff-free…
Read MoreToday, President Trump signed a partial trade agreement with China. This deal is considered Phase 1 of ongoing trade negotiations between the United States and China…
Read MoreU.S. Senator and presidential candidate Elizabeth Warren recently released a statement on her 2020 healthcare plan. She wants to allow the government to hijack the Bayh-Dole Act’s March-in provision to revoke patent protections from pharmaceutical innovators in an attempt to artificially lower drug prices…
Read MorePolicymakers and pundits from across the political spectrum are celebrating a newly unveiled plan to pass the United States – Mexico – Canada Agreement (USMCA) on trade. U.S. Trade Representative Robert Lighthizer has even called it a model for future trade agreements. The USMCA contains many improvements over its 1994 predecessor, the North American Free Trade Agreement (NAFTA) and should be passed expeditiously. Yet while there are many positive aspects to the USMCA, the agreement is far from perfect and should not be viewed as any kind of “model” for future trade agreements…
Read MoreFor months, the Trade Alliance to Promote Prosperity has written about how H.R. 3, the “Lower Drugs Costs Now” Act, would be detrimental to American healthcare and to Americans’ health…
Read MoreThe Council of Economic Advisors just came out with a new analysis of H.R. 3, the “Lower Drug Costs Now Act of 2019.”
This bill seeks to lower prices for certain drugs by forcing drug manufacturers to accept prices set by the federal government or otherwise…
Read MoreOver the Thanksgiving holiday weekend, we passed a milestone: It’s now been over one year since President Trump signed the U.S.-Mexico-Canada Agreement (USMCA) on trade—over a year! The holdup: House Speaker Nancy Pelosi…
Read MoreTime is running out for Congress to approve the USMCA, and some members of Congress are expressing frustration with the leadership. Senate Finance Committee Chairman Chuck Grassley (R-Iowa), previously optimistic about passage, has said he is now concerned about ratification of the USMCA…
Read MoreMost people probably agree that there should be protections against the criminals who pirate films, violate patents, plagiarize books and counterfeit artworks. Time and again, we have heard stories about imitations coming from overseas. Thus, it is especially important that American innovators…
Read MoreWord on the Hill is that House Speaker Nancy Pelosi might be trying to strip the US-Mexico-Canada Agreement (USMCA) of its Intellectual Property chapter. Yet one of the greatest benefits of the USMCA over its precursor, NAFTA, is that it strengthens intellectual property protections for American innovators.
Here are some of the comparisons:…
Read MoreU.S. House Speaker Nancy Pelosi has proposed a sweeping prescription drug bill that would hurt patients and stifle innovation. Her bill, H.R. 3, would impose crushing taxes…
Read MoreIn the upcoming days, committees in the U.S. House of Representatives will discuss H.R. 3, Speaker Nancy Pelosi’s radical prescription drug pricing bill that would impose a tax of up to 95 percent (!) on hundreds of prescription drugs. This draconian bill would also…
Read MoreOn Wall Street, stock and commodity prices climbed immediately, suggesting that the president’s optimism over the prospect of a deal with China was infectious. Indeed, many on Wall Street and across the country were waiting eagerly to hear positive news come from the talks with China after weeks and even months of stalemate…
Read MoreLast week, U.S. Rep. David Cicilline of Rhode Island introduced the “Affordable Prescriptions for Patients Through Promoting Competition Act,” which could more accurately have been named the…
Read MoreIn the 1980s, European investment in drug research was 24 percent higher than in the United States. But then, European officials decided to impose socialist price controls. Today, European investment in drug research is 40 percent lower than American investment is…
Read More